Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 209Stomach Neoplasms 37Neoplasm Metastasis 26Neoplasms 18HER2-positive Breast Cancer 14Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 10Brain Neoplasms 10Esophageal Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Urologic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3HER2-positive Gastric Cancer 3Carcinoma 3Breast Cancer Metastatic 3Urinary Bladder Neoplasms 2Solid Tumors 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2HER2-positive Early Breast Cancer 2Cholangiocarcinoma 2Breast Diseases 2

Interventions

zenocutuzumab 2seribantumab 2pembrolizumab 1patritumab 1osimertinib 1exemestane 1cemiplimab 1Vinorelbine 1Vascular Endothelial Growth Factor A 1Trastuzumab 1Paroxetine 1Paclitaxel 1Letrozole 1Itraconazole 1Fulvestrant 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lethal Congenital Contracture Syndrome 2 × Trastuzumab × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡